Based on these actions, some compounds, such as EPZ004777 and EPZ5676, that target the catalytic activity of DOT1L have been developed for the treatment of MLL-induced leukemia as well as other solid tumors (Stein et al., 2018; Yang et al., 2019; Sarno et al., 2020). The gene discussed is KMT2A; the disease is leukemia.